Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Donepezil Long-term Follow-up in Alzheimer's (ALF Study)
NCT00165724Phase 4Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Jun 2004
- Primary completion
- Jul 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of donepezil in Alzheimer's disease (AD), sponsored by Eisai Co., Ltd. Primary endpoint: Alzheimer's Disease Assessment Scale-cognitive subscale at 48 weeks. Started Jun 2004; status: completed.
02
Drugs
donepezil
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT00165724.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00165724.